Investigating how HIV-1 integrase affects virus formation and targeting it with new drugs
Official title: Role of HIV-1 integrase in virion morphogenesis and its targeting by allosteric integrase inhibitors
Funded at University of Colorado Denver · NIH-11020163 · Data updated 2026-11-12
This study is looking at how a part of the HIV virus called integrase helps the virus form and how new medications can block it, with the goal of finding better treatments for people living with tough-to-treat HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $847,141 |
| NIH project number | 1R01AI184419-01A1 |
| Project ID | NIH-11020163 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with multi-drug resistant HIV-1 who have not responded to standard treatments.
✕Less likely to help
Patients who are not infected with HIV-1 or those with drug-sensitive strains of the virus may not benefit from this research.
What this research studies
This research focuses on understanding the role of HIV-1 integrase in the formation of the virus and how it can be targeted by new types of medications called allosteric integrase inhibitors. The team is exploring how integrase interacts with the viral RNA to ensure the virus is properly formed and infectious. By studying these interactions, they aim to develop innovative treatments for patients with multi-drug resistant HIV-1. The research includes both laboratory experiments and clinical trials of promising new drugs.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with drug-resistant HIV-1 infections.
How similar studies have gone: Previous research has shown promise in targeting integrase with novel inhibitors, indicating potential for success in this approach.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Kvaratskhelia, Mamuka — University of Colorado Denver
- Study coordinator: Kvaratskhelia, Mamuka
Related research
Other NIH-funded projects on the same topics.
-
Understanding how alcohol and how couples talk about consent affect intimate partner sexual violence
This project studies how alcohol use and how partners communicate about consent influence intimate partner sexual violence among sexual minority and heterosexual couples.
-
How proteins change and move as heart cells develop
This grant aims to map how protein turnover changes as human iPSCs turn into cardiomyocytes and other cell types, using new labeling and mass-spectrometry methods.
-
Center for Health, Work and Environment
A national center dedicated to improving health in people who work, by studying how jobs affect well-being and safety.
-
Subtyping Core for Research on the Causes of Type 2 Diabetes (SCORE-T2D)
A new U01 grant from a university research team aims to understand why Type 2 diabetes differs so much between people and how to tailor prevention and treatment.
-
Expanded antibody-based clues to TB risk in people with HIV
A clinician-scientist seeks to understand how antibodies in people with HIV may drive the progression from latent TB to active TB, with the goal of identifying clues that could guide future care.
-
Human Trisome Project in Latin America Network
A large, multi-site study of people with Down syndrome across Latin America to better understand health and aging in DS.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.